Send to

Choose Destination
Rev Med Inst Mex Seguro Soc. 2019 Jul 31;57(2):65-73.

Piperacillin/tazobactam plus amikacin vs. piperacilin/tazobactam: treatment for children with febrile neutropenia

[Article in Spanish; Abstract available in Spanish from the publisher]

Author information

Instituto Mexicano del Seguro Social, Coordinación de Investigación en Salud, Unidad de Investigación en Epidemiología Hospitalaria. Ciudad de México, México


in English, Spanish


Pediatric patients with febrile neutropenia usually receive a combination of broad spectrum antimicrobials. Treatment without aminoglycoside seems to have advantages.


To compare the efficacy of piperacillin/tazobactam plus amikacin versus piperacillin/tazobactam.


Randomized, open label, controlled clinical trial. Sample size for an efficacy of 55%, and delta of 25%; 80 episodes were required for each group. Selection criteria were patients with febrile neutropenia, candidates to receive parenteral antimicrobial treatment; they were randomized to one of two groups, piperacillin/tazobactam plus amikacin (Group A), or piperacillin/tazobactam (Group B). The outcomes were failure, adverse events and death. Mantel-Haenszel chi squaretest and exact Fisher test were used. Reduction of relative and absolute risk (RRR and ARR), 95% confidence intervals (CI 95%) and number needed to treat (NNT) were calculated.


88 Episodes were analyzed in group A and 76 in group B. There was no statistical difference in general characteristics of patients or type of infections. There was not significant statistical difference in: failure 31.8% group A, 30.2% group B (RR 1.05, CI 95% 0.66-1.66, p = 0.86), or adverse events (one in each group). The RRR was 1.5%, and ARR 2%, with a NNT of 67.


Piperacillin/tazobactam without amikacin was as effective as combination therapy in pediatric patients with febrile neutropenia.


Neoplasms; Febrile Neutropenia; Piperacillin; Tazobactam; Amikacin


Supplemental Content

Loading ...
Support Center